000			02267 a2200637 4500
005			20250514180848.0
264		0	_c20040427
008			200404s 0 0 ger d
022			_a1438-3276
040			_aNLM _beng _cNLM
100	1		_aKellerer, M
245	0	0	_a[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy]. _h[electronic resource]
260			_bMMW Fortschritte der Medizin _cDec 2003
300			_aI-X; quiz XI-XII p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Review
650	0	4	_a1-Deoxynojirimycin _xanalogs & derivatives
650	0	4	_aAcarbose _xadministration & dosage
650	0	4	_aAged
650	0	4	_aBlood Glucose _xanalysis
650	0	4	_aCarbamates _xadministration & dosage
650	0	4	_aContraindications
650	0	4	_aCyclohexanes _xadministration & dosage
650	0	4	_aDiabetes Mellitus, Type 2 _xblood
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEnzyme Inhibitors _xadministration & dosage
650	0	4	_aFasting
650	0	4	_aFollow-Up Studies
650	0	4	_aGermany _xepidemiology
650	0	4	_aGlucosamine _xadministration & dosage
650	0	4	_aGlyburide _xadministration & dosage
650	0	4	_aGlycated Hemoglobin _xanalysis
650	0	4	_aGlycoside Hydrolase Inhibitors
650	0	4	_aHumans
650	0	4	_aHypoglycemia _xchemically induced
650	0	4	_aHypoglycemic Agents _xadministration & dosage
650	0	4	_aImino Pyranoses
650	0	4	_aInsulin _xadministration & dosage
650	0	4	_aMetformin _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aNateglinide
650	0	4	_aObesity _xcomplications
650	0	4	_aPatient Compliance
650	0	4	_aPhenylalanine _xadministration & dosage
650	0	4	_aPioglitazone
650	0	4	_aPiperidines _xadministration & dosage
650	0	4	_aPractice Guidelines as Topic
650	0	4	_aRisk Factors
650	0	4	_aRosiglitazone
650	0	4	_aSulfonylurea Compounds _xadministration & dosage
650	0	4	_aThiazolidinediones _xadministration & dosage
650	0	4	_aTime Factors
700	1		_aJakob, S
700	1		_aLinn, T
700	1		_aHaslbeck, M
773	0		_tMMW Fortschritte der Medizin _gvol. 145 _gno. 51-52 _gp. I-X; quiz XI-XII
999			_c14696104 _d14696104